SGLT2-inhibitor associated ketoacidosis
Conditions
Interventions
Group 1: Data from electronic patient files from all Patients on Long-Term SGLT2 Inhibitor Therapy Undergoing Surgical Procedures at the University Hospital Augsburg from 01.01.2023 to 31.12.2024 will
Sponsors
Universitätsklinikum Augsburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Preoperative long-term use of an SGLT2 inhibitor approved in Germany - Patients undergoing a surgical procedure at the University Hospital Augsburg between January 1, 2023, and December 31, 2024 - Perioperative point-of-care (POC) measurement of serum ketone bodies
Exclusion criteria
Exclusion criteria: - Type 1 diabetes mellitus - eGFR 24 hours
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of perioperative EDKA in Patients on Long-Term SGLT2 Inhibitor Therapy Undergoing Surgical Procedures at the University Hospital Augsburg from 01.01.2023 to 31.12.2024. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Type and duration of the surgical procedure - Anesthesia technique used - Time interval between the last SGLT2 inhibitor intake and the surgical procedure - Guideline-compliant preoperative discontinuation of SGLT2 inhibitors (72h) - Difference in measured ketone levels in relation to the preoperative pause of SGLT2 inhibitor intake - Hospital length of stay in patients with EDKA compared to those without EDKA | — |
Countries
Germany
Contacts
Public ContactPhilipp Simon
Universitätsklinikum Augsburg
Outcome results
None listed